MX2017010623A - Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral. - Google Patents
Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral.Info
- Publication number
- MX2017010623A MX2017010623A MX2017010623A MX2017010623A MX2017010623A MX 2017010623 A MX2017010623 A MX 2017010623A MX 2017010623 A MX2017010623 A MX 2017010623A MX 2017010623 A MX2017010623 A MX 2017010623A MX 2017010623 A MX2017010623 A MX 2017010623A
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- infection
- patient
- formula
- viral infection
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title abstract 4
- 230000009385 viral infection Effects 0.000 title abstract 4
- 230000002265 prevention Effects 0.000 title 1
- XNMYNYSCEJBRPZ-UHFFFAOYSA-N 2-[(3-butyl-1-isoquinolinyl)oxy]-N,N-dimethylethanamine Chemical class C1=CC=C2C(OCCN(C)C)=NC(CCCC)=CC2=C1 XNMYNYSCEJBRPZ-UHFFFAOYSA-N 0.000 abstract 3
- 208000015181 infectious disease Diseases 0.000 abstract 3
- 239000002207 metabolite Substances 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
- 230000000798 anti-retroviral effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un derivado de quinoleína de la fórmula (I) (ver Fórmula) o cualquiera de sus sales farmacéuticamente aceptables, o cualquiera de sus metabolitos, para su uso para tratar o prevenir una infección viral, en particular una infección provocada por VIH o una afección relacionada con VIH en un paciente; y luego terminar el tratamiento cuando: la carga viral es baja o indetectable; y/o se mantiene o restaura el nivel de recuento de las células CD4+. La presente invención se refiere además a un derivado de quinoleína de la fórmula (I) según se define en la reivindicación 1, o cualquiera de sus sales y metabolitos farmacéuticamente aceptables, para su uso para tratar o prevenir una infección viral, en particular una infección provocada por VIH o una afección relacionada con VIH en un paciente, para el cual se ha indicado una ineficacia o una disminución de la eficacia de un tratamiento antirretroviral previo y un derivado de quinoleína de la fórmula (I) como se ha definido anteriormente, o cualquiera de sus sales y metabolitos farmacéuticamente aceptables, para su uso para tratar o prevenir una infección viral, en particular una infección provocada por VIH o una afección relacionada con VIH en un paciente, en donde el paciente está infectado por una cepa viral resistente a los fármacos, y más particularmente por una cepa de VIH resistente a los fármacos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305277.4A EP3058940A1 (en) | 2015-02-23 | 2015-02-23 | Quinoline derivatives for use in the treatment or prevention of viral infection |
| PCT/EP2016/053535 WO2016135055A1 (en) | 2015-02-23 | 2016-02-19 | Quinoline derivatives for use in the treatment or prevention of viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017010623A true MX2017010623A (es) | 2018-03-12 |
| MX382760B MX382760B (es) | 2025-03-13 |
Family
ID=52629499
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017010623A MX382760B (es) | 2015-02-23 | 2016-02-19 | Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral. |
| MX2021006636A MX2021006636A (es) | 2015-02-23 | 2017-08-17 | Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021006636A MX2021006636A (es) | 2015-02-23 | 2017-08-17 | Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10806729B2 (es) |
| EP (2) | EP3058940A1 (es) |
| JP (1) | JP6826988B2 (es) |
| KR (1) | KR102650958B1 (es) |
| CN (1) | CN107635559A (es) |
| AU (1) | AU2016223599B2 (es) |
| BR (1) | BR112017017505A2 (es) |
| CA (1) | CA2975777C (es) |
| DK (1) | DK3261642T3 (es) |
| ES (1) | ES2882542T3 (es) |
| HR (1) | HRP20211172T1 (es) |
| HU (1) | HUE055592T2 (es) |
| LT (1) | LT3261642T (es) |
| MX (2) | MX382760B (es) |
| PL (1) | PL3261642T3 (es) |
| PT (1) | PT3261642T (es) |
| RS (1) | RS62173B1 (es) |
| RU (1) | RU2723016C2 (es) |
| SI (1) | SI3261642T1 (es) |
| WO (1) | WO2016135055A1 (es) |
| ZA (1) | ZA201705634B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
| EP3594205A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-aryl derivatives for treating a rna virus infection |
| EP3594206A1 (en) | 2018-07-09 | 2020-01-15 | Abivax | Phenyl-n-quinoline derivatives for treating a rna virus infection |
| EP3669873A1 (en) * | 2018-12-20 | 2020-06-24 | Abivax | Quinoline derivatives for use ine the traeatment of inflammation diseases |
| KR20220104773A (ko) * | 2019-11-26 | 2022-07-26 | 바이오트론 리미티드 | Hiv-1 감염을 치료하는 방법 |
| KR102399037B1 (ko) * | 2020-01-06 | 2022-05-17 | 성균관대학교산학협력단 | 아민화된 아진의 신규한 제조방법 |
| EP3881844A1 (en) * | 2020-03-20 | 2021-09-22 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP4121053A1 (en) * | 2020-03-20 | 2023-01-25 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| EP3884946A1 (en) * | 2020-03-25 | 2021-09-29 | Abivax | Compounds for treating or preventing a coronaviridae infection & methods and uses for assessing the occurrence of a coronaviridae infection |
| WO2023126951A1 (en) * | 2022-01-03 | 2023-07-06 | Yeda Research And Development Co. Ltd. | Inhibitors of autophagy-related protein-protein interactions |
| CN114931580B (zh) * | 2022-05-26 | 2024-04-19 | 军事科学院军事医学研究院军事兽医研究所 | 依曲韦林在抗狂犬病病毒中的应用和抗狂犬病病毒药物的筛选方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354853A (en) * | 1993-03-12 | 1994-10-11 | Genzyme Corporation | Phospholipid-saccharide conjugates |
| WO2010143169A2 (en) * | 2009-06-12 | 2010-12-16 | Société Splicos | Compounds useful for treating aids |
| EP2465502A1 (en) * | 2010-12-15 | 2012-06-20 | Société Splicos | Compounds useful for treating AIDS |
| EP2757161A1 (en) * | 2013-01-17 | 2014-07-23 | Splicos | miRNA-124 as a biomarker of viral infection |
| MX382692B (es) * | 2013-07-05 | 2025-03-13 | Abivax | Compuestos bicíclicos útiles para el tratamiento de enfermedades causadas por retrovirus. |
| EP2975034A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | A quinoline derivative for the treatment of inflammatory diseases and AIDS |
| EP2974729A1 (en) | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
-
2015
- 2015-02-23 EP EP15305277.4A patent/EP3058940A1/en not_active Withdrawn
-
2016
- 2016-02-19 BR BR112017017505-3A patent/BR112017017505A2/pt not_active Application Discontinuation
- 2016-02-19 HU HUE16705929A patent/HUE055592T2/hu unknown
- 2016-02-19 MX MX2017010623A patent/MX382760B/es unknown
- 2016-02-19 HR HRP20211172TT patent/HRP20211172T1/hr unknown
- 2016-02-19 RS RS20210964A patent/RS62173B1/sr unknown
- 2016-02-19 KR KR1020177026021A patent/KR102650958B1/ko active Active
- 2016-02-19 PT PT167059294T patent/PT3261642T/pt unknown
- 2016-02-19 DK DK16705929.4T patent/DK3261642T3/da active
- 2016-02-19 AU AU2016223599A patent/AU2016223599B2/en not_active Ceased
- 2016-02-19 CN CN201680011581.6A patent/CN107635559A/zh active Pending
- 2016-02-19 ES ES16705929T patent/ES2882542T3/es active Active
- 2016-02-19 EP EP16705929.4A patent/EP3261642B1/en active Active
- 2016-02-19 LT LTEP16705929.4T patent/LT3261642T/lt unknown
- 2016-02-19 WO PCT/EP2016/053535 patent/WO2016135055A1/en not_active Ceased
- 2016-02-19 PL PL16705929T patent/PL3261642T3/pl unknown
- 2016-02-19 US US15/552,921 patent/US10806729B2/en active Active
- 2016-02-19 JP JP2017544314A patent/JP6826988B2/ja active Active
- 2016-02-19 CA CA2975777A patent/CA2975777C/en active Active
- 2016-02-19 RU RU2017128644A patent/RU2723016C2/ru active
- 2016-02-19 SI SI201631277T patent/SI3261642T1/sl unknown
-
2017
- 2017-08-17 MX MX2021006636A patent/MX2021006636A/es unknown
- 2017-08-18 ZA ZA2017/05634A patent/ZA201705634B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170125850A (ko) | 2017-11-15 |
| DK3261642T3 (da) | 2021-08-09 |
| RU2017128644A (ru) | 2019-03-25 |
| HUE055592T2 (hu) | 2021-12-28 |
| MX382760B (es) | 2025-03-13 |
| LT3261642T (lt) | 2021-07-26 |
| RU2017128644A3 (es) | 2019-04-15 |
| JP6826988B2 (ja) | 2021-02-10 |
| PL3261642T3 (pl) | 2021-11-15 |
| WO2016135055A1 (en) | 2016-09-01 |
| CA2975777A1 (en) | 2016-09-01 |
| AU2016223599B2 (en) | 2021-03-11 |
| EP3261642B1 (en) | 2021-05-19 |
| RS62173B1 (sr) | 2021-08-31 |
| HRP20211172T1 (hr) | 2021-12-24 |
| EP3058940A1 (en) | 2016-08-24 |
| ES2882542T3 (es) | 2021-12-02 |
| ZA201705634B (en) | 2018-12-19 |
| MX2021006636A (es) | 2021-07-07 |
| BR112017017505A2 (pt) | 2018-04-17 |
| CN107635559A (zh) | 2018-01-26 |
| EP3261642A1 (en) | 2018-01-03 |
| PT3261642T (pt) | 2021-08-02 |
| KR102650958B1 (ko) | 2024-03-22 |
| US20180028522A1 (en) | 2018-02-01 |
| AU2016223599A1 (en) | 2017-08-31 |
| JP2018505909A (ja) | 2018-03-01 |
| CA2975777C (en) | 2022-12-13 |
| US10806729B2 (en) | 2020-10-20 |
| RU2723016C2 (ru) | 2020-06-08 |
| SI3261642T1 (sl) | 2021-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010623A (es) | Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral. | |
| CY1125202T1 (el) | Συνδυασμοι που περιλαμβανουν παραγωγα 5-φαινοξυ-3η-πυριμιδιν-4-ονης και η χρηση αυτων για την προφυλαξη ή αγωγη λοιμωξης απο hiv | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| ECSP12012106A (es) | Terapia antiviral | |
| MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019012035A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CU24525B1 (es) | Derivado de quinoleína para tratar y prevenir infecciones virales | |
| UY36340A (es) | Derivados de indoles mono- o disustituidos como inhibidores de la replicación del virus del dengue | |
| CO2021012579A2 (es) | Compuestos útiles en la terapia del vih | |
| EA201590862A1 (ru) | Фармацевтические композиции | |
| MX2018003256A (es) | Derivados de indol mono- o disustituidos como inhibidores de la replicacion viral del dengue. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| MX2018004304A (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| EA201790495A1 (ru) | Фармацевтические композиции длительного действия | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| MX2017009863A (es) | Agente preventivo y/o terapeutico de enfermedad inmune. | |
| MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX2019000645A (es) | Uso de xibornol como agente activo en el tratamiento de infecciones virales. |